Guru Ownership Trend
Guru Analysis for BioCryst Pharmaceuticals, Inc. (BCRX)
BioCryst Pharmaceuticals, Inc. (BCRX), a key player in the Healthcare sector, continues to attract institutional attention.
As of Q4 2025, a total of 8 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $66.84 M.
Top institutional holders include Ken Fisher and Renaissance Technologies (RenTech).
Institutional sentiment is currently Bullish. This is evidenced by a $25,462.13 net inflow during the quarter.
Recent activity highlights Steven Cohen who increased their stake by 409.5%. Conversely, Ray Dalio reduced exposure by 42.8%.
Key Holders
Top 5 by Value
Top 5 by Conviction
Recent Activity Breakdown (Q4 2025)
Guru Consensus (Q4 2025)
FAQs for BioCryst Pharmaceuticals, Inc. (BCRX)
Major holders include Ken Fisher ($19.25 M), Renaissance Technologies (RenTech) ($16.6 M), Steven Cohen ($9.47 M). According to the latest reported data, 8 tracked investment managers collectively hold approximately 7.33 M shares.
According to the latest 13F reporting period, sentiment appears Bullish (Net Buying). There was a net inflow of $25,462.13, with 3 managers increasing positions and 6 managers reducing holdings.
During the most recent reporting period, 5 managers trimmed their positions, while 1 fully exited BCRX. The total reported sell value was $8.04 M.
Yes, 0 managers opened new positions in BCRX, and 3 increased their existing holdings. The total reported buy value was $8.06 M.
